<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="39" ids="10110">AZT</z:chebi> has induced a <z:hpo ids='HP_0001972'>macrocytic anemia</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> patients on long term <z:chebi fb="39" ids="10110">AZT</z:chebi> therapy </plain></SENT>
<SENT sid="1" pm="."><plain>It is generally assumed that DNA elongation is stopped by the insertion of <z:chebi fb="39" ids="10110">AZT</z:chebi> into the chain in place of <z:chebi fb="0" ids="17748">thymidine</z:chebi> thus preventing the phosphate <z:chebi fb="10" ids="29191">hydroxyl</z:chebi> linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation </plain></SENT>
<SENT sid="2" pm="."><plain>CBA/Ca male mice started on <z:chebi fb="39" ids="10110">AZT</z:chebi> 0.75 mg/ml <z:chebi fb="2" ids="29375,33813">H2O</z:chebi> at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml <z:chebi fb="2" ids="29375,33813">H2O</z:chebi> for a group, another group removed from <z:chebi fb="39" ids="10110">AZT</z:chebi> to see recovery, and third group remained on 0.75 mg </plain></SENT>
<SENT sid="3" pm="."><plain>At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6) </plain></SENT>
<SENT sid="4" pm="."><plain>Histological examination on 9 of 10 mice with such <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> showed changes compatible with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>A variety of histological patterns was observed </plain></SENT>
<SENT sid="6" pm="."><plain>There were two cases of hypocellular <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>, two cases of hypersegmented myelodysplastic <z:mp ids='MP_0000322'>granulocytosis</z:mp>, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of <z:e sem="disease" ids="C0023462" disease_type="Neoplastic Process" abbrv="">megakaryocytic myelosis</z:e> associated with a hyperplastic marrow, <z:e sem="disease" ids="C0026986" disease_type="Neoplastic Process" abbrv="MDS">dysmyelopoiesis</z:e> and a <z:e sem="disease" ids="C0151773" disease_type="Disease or Syndrome" abbrv="">hypocellular marrow</z:e> and two cases of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> with dyserythropoiesis, <z:mp ids='MP_0005639'>hemosiderosis</z:mp> and a <z:e sem="disease" ids="C0151773" disease_type="Disease or Syndrome" abbrv="">hypocellular marrow</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Above mentioned <z:chebi fb="39" ids="10110">AZT</z:chebi> incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
</text></document>